Searchable abstracts of presentations at key conferences in endocrinology

ea0011p547 | Endocrine tumours and neoplasia | ECE2006

Efficacy and safety of high doses of long-acting somatostatin analogues for treatment of well differentiated functioning neuroendocrine tumors

Ferolla P , Faggiano A , Pivonello R , Lombardi G , Angeletti G , Colao A , Santeusanio F

Introduction: Somatostatin analogues (SSA) represent the main therapeutic option in patients affected with functioning well-differentiated neuroendocrine tumors (NET). However, after a variable time from the start of the therapy tachyphylaxys may cause lack of control of clinical syndrome and progression of the disease.Aim: The aim of this preliminary study was to evaluate efficacy in terms of reduction of circulating markers, control of the clinical syn...

ea0032p1080 | Thyroid cancer | ECE2013

A single-center, open-label, phase II, proof-of-concept study with pasireotide long-acting release in patients with progressive medullary thyroid cancer: 6-month evaluation

Faggiano Antongiulio , Ferolla Piero , Vitale Giovanni , Del Prete Michela , Ramundo Valeria , Esposito Raffaella , Marotta Vincenzo , Marciello Francesca , Carratu Anna Chiara , Camera Luigi , Fonti Rosi , Colao Annamaria

Introduction: Medullary thyroid cancer (MTC) is a well-differentiated neuroendocrine tumor in which somatostatin receptor (sst) expression is higher for sst1 and sst5 than for sst2. This may explain why the available sst2–selective analogues do not work in these patients and why pasireotide (SOM230), a novel, multi-receptor targeted somatostatin analogue with high-binding affinity for sst1,2,3 and sst5 coul...

ea0014p142 | (1) | ECE2007

Dopamine receptor expression and dopamine agonist effectiveness in post-surgical persistent medullary thyroid cancer

Pivonello Rosario , Ferolla Piero , Faggiano Antongiulio , Ferone Diego , Cerasola Enrica , Angeletti Gabriella , Santeusanio Fausto , Minuto Francesco , Lombardi Gaetano , Lamberts Steven WJ , Hofland Leo J , Colao Annamaria

Dopamine receptors was suggested to be expressed in medullary thyroid cancer (MTC). The aim of the current study was to evaluate the expression of D2 dopamine receptor in MTC and the effectiveness of the dopamine agonist cabergoline in patients with MTC. Five paraffin-embedded cases of MTC obtained after thyroidectomy were used to evaluate D2 receptor expression by immunohistochemistry. Fifteen patients (7 males, 8 females, 36–78 years) with post-sur...

ea0011p530 | Endocrine tumours and neoplasia | ECE2006

18F-deoxy-D-glucose positron emission tomography (FDG_PET) increases the detection rate of recurrent or residual medullary thyroid cancer

Faggiano AF , Ferolla PF , Pezzullo LC , Chiofalo MC , Milone FM , Mozzillo NM , Scarpelli GS , Santeusanio FS , Angeletti GA , Lombardi GL , Colao AC

Surgical treatment is the first therapeutic option in patients affected with medullary thyroid carcinoma (MTC). However, cure-rates are often low due to the high frequency of loco-regional metastases and recurrences. Therefore, post-operative hyper-calcitoninemia is a common feature in CMT. Despite these findings, traditional imaging techniques are often unable to localize tumour foci. In the last years the availability of new morpho-functional techniques might offer new chanc...

ea0032p518 | Endocrine tumours and neoplasia | ECE2013

Neuroendocrine tumours (NETs) of lung: new data on atypical carcinoid and large cell neuroendocrine carcinoma from a French-Italian multicentric study

Marciello Francesca , Mercier Olaf , Ferolla Piero , David Planchard , Filosso Pier Luigi , Chapelier Alain , Grimaldi Franco , de Latour Bertrand Richard , Blanco Giusy , Guigay Joel , Monaco Guglielmo , Dartevelle Philippe , Papotti Mauro , Scoazec Jean-Yves , Colao Annamaria , Baudin Eric , Faggiano Antongiulio

Introduction: Natural history of lung neuroendocrine tumours (NETs) and in particular of two histological subtypes, atypical carcinoid (AC) and large cell neuroendocrine carcinoma (LCNEC), is poorly known.Aim of the study was to determine disease-free survival (DFS) and overall survival (OS) of sporadic, resectable, non-metastatic lung AC and LNEC.Patients and methods: This retrospective study involved 116 consecutive patients surg...